Tzoran Inna, Papadakis Emmanouil, Brenner Benjamin, Valle Reina, López-Jiménez Luciano, García-Bragado Fernando, Riera-Mestre Antoni, Villalobos Aurora, Quintavalla Roberto, Monreal Manuel
Department of Internal Medicine C, Rambam Health Care Campus, Haifa, Israel.
Haematology and Hemostasis Unit, Hospital Papageorgiou, Saloniki, Greece.
Thromb Res. 2017 Mar;151 Suppl 1:S11-S15. doi: 10.1016/S0049-3848(17)30060-9.
In patients with venous thromboembolism (VTE) and factor V Leiden (FVL) or prothrombin 20210G-A mutation (PTM), the influence of gender on outcome has not been consistently studied.
We used the RIETE (Registro Informatizado Enfermedad TromboEmbolica) database to assess the existence of gender differences in the rate of VTE recurrences (deep vein thrombosis [DVT] or pulmonary embolism [PE]) or major bleeding during the course of anticoagulation and after its discontinuation in FVL and PTM carriers.
From March 2001 to September 2016, 11,224 VTE patients underwent thrombophilia testing. Of these, 1,563 were FVL carriers (863 men and 700 women) and 1,231 were PTM carriers (659 men and 572 women). During the course of anticoagulant therapy, men with FVL had a 6-fold higher rate of VTE recurrences than major bleeds (31 vs. 5 events). In women with FVL, the rate of VTE recurrences was 2-fold higher (16 vs. 8), as was in men (17 vs. 8) or women (17 vs. 9) with PTM. After discontinuing anticoagulation, men with FVL had a 3-fold higher rate of DVT recurrences than women (hazard ratio [HR]: 3.13; 95% CI: 1.79-5.67), with no differences in PE recurrences. Among patients with PTM, there were no gender differences in the rate of DVT (HR: 1.89; 95% CI: 1.00-3.65) or PE recurrences (HR: 1.82; 95% CI: 0.83-4.12).
During the anticoagulation course, men with FVL are at a much higher risk for VTE recurrences than bleeding. After discontinuing anticoagulation, men with FVL are at an increased risk for DVT recurrences.
在静脉血栓栓塞症(VTE)合并因子V莱顿突变(FVL)或凝血酶原20210G-A突变(PTM)的患者中,性别对预后的影响尚未得到一致研究。
我们使用RIETE(静脉血栓栓塞疾病信息登记处)数据库,评估FVL和PTM携带者在抗凝治疗期间及停药后VTE复发率(深静脉血栓形成[DVT]或肺栓塞[PE])或大出血方面是否存在性别差异。
2001年3月至2016年9月,11224例VTE患者接受了血栓形成倾向检测。其中,1563例为FVL携带者(863例男性和700例女性),1231例为PTM携带者(659例男性和572例女性)。在抗凝治疗期间,携带FVL的男性VTE复发率比大出血率高6倍(31次对5次)。携带FVL的女性中,VTE复发率高2倍(16次对8次),携带PTM的男性(17次对8次)或女性(17次对9次)也是如此。停药后,携带FVL的男性DVT复发率比女性高3倍(风险比[HR]:3.13;95%置信区间[CI]:1.79-5.67),PE复发率无差异。在携带PTM的患者中,DVT(HR:1.89;95%CI:1.00-3.65)或PE复发率(HR:1.82;95%CI:0.83-4.12)无性别差异。
在抗凝治疗期间,携带FVL的男性VTE复发风险比出血风险高得多。停药后,携带FVL的男性DVT复发风险增加。